论文部分内容阅读
为了探讨bcl－2和突变型P53蛋白在乳腺癌中存在的相互关系·应用免疫组化LSAB法观察了它们在145例乳腺癌组织中的表达。结果；bcl－2表达率为42．1％，P53为49.0％。P53表达率越高．bc1－2表达率越低，两者有明显负相关性（P＜0.01）。两种腐蛋白表达情况与乳腺癌病理分级有关，p53阳性者分化差，而bcl-2阳性者分化较好（P＜0，05）。它们的表达与肿瘤坏死和核分裂也有明显关系,bcl-2阳性者坏死明显少于p53阳性者;bcl-2阳性者核分裂少,p53阳性者核分裂多（p＜0.05）。表明；p53与乳腺癌预后差的参数有关，而bcl-2与好的临床病理参数有联系。bcl-2的表达可能受到p53的调控。
In order to investigate the relationship between bcl-2 and mutant P53 protein in breast cancer, their expression in 145 breast cancer tissues was observed by immunohistochemical LSAB method. Results; bcl-2 expression rate was 42.1%, P53 was 49.0%. The higher the expression rate of P53. The lower the expression rate of bcl-2, there was a significant negative correlation between the two (P<0.01). The expression of the two rotins was related to the pathological grade of breast cancer. The differentiation of p53-positive patients was poor, while those of bcl-2-positive patients were well differentiated (P<0,05). Their expression was also associated with tumor necrosis and nuclear fission. Bcl-2 positive patients had significantly less necrosis than p53 positive patients; bcl-2 positive patients had less nuclear division, and p53 positive patients had more nuclear division (p<0.05). It was shown that p53 is associated with poor prognosis of breast cancer, and bcl-2 is associated with good clinicopathological parameters. The expression of bcl-2 may be regulated by p53.